LATEST ONCOPRESCRIBE UPDATES
FDA Approves ALECENSA® as Adjuvant Treatment for ALK-Positive Non Small Cell Lung Cancer
Long Term Benefits of RUBRACA® Maintenance in Newly Diagnosed Ovarian Cancer
Omitting Axillary Lymph Node Dissection in Breast Cancer with Sentinel-Node Metastases
FDA Approves ENHERTU® for Unresectable or Metastatic HER2-Positive Solid Tumors
April 2024: Current Tumor-Agnostic Therapies
Enfortumab Vedotin plus Pembrolizumab: A Breakthrough in Locally Advanced or Metastatic Urothelial Carcinoma
Novel Prognostic Factors for Treatment-Free Remission in Chronic Myeloid leukemia
Neoadjuvant KEYTRUDA® plus Chemotherapy Significantly Improves EFS in Early Stage High Risk Triple Negative Breast Cancer